Palbociclib (PD-0332991) HCl

Licensed by Pfizer Catalog No.S1116

Palbociclib (PD-0332991) HCl Chemical Structure

Molecular Weight(MW): 483.99

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Size Price Stock Quantity  
USD 110 In stock
USD 170 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

8 Customer Reviews

  • PD-0332991 causes inhibition of proliferation of EAC cells in a dose-dependent manner. Western blots showing the phosphorylation status of pRB at Ser780 and Ser795 after incubation with 125 nmol/L PD-0332991 for 24 and 72 hours. Reduction in cyclin A expression and the expression of RB2 (p130) tumor suppressor 72 hours after PD-0332991 treatment are shown (bottom). Total pRB (RB1) and actin are loading controls and T293 cell lysate (293) is a positive control for total pRB and phospho-pRB (Ph-RB). E, anchorage-independent growth of the 3 cell lines in the presence or absence (Cnt) of 125 nmol/L PD-0332991 for 3 weeks.

    Clin Cancer Res 2011 17(13), 4513-22. Palbociclib (PD-0332991) HCl purchased from Selleck.

    b, c MelJuso cells were treated for 12–48 h with 1 µM Selumetinib or 5 µM Palbociclib and the cells were fixed, stained with propidium iodide and cell cycle distribution was determined by flow cytometry (b) and whole cell extracts were fractionated by SDS-PAGE, transferred onto PVDF membrane and immuno-blotted with the indicated antibodies (c). Data is from a single experiment representative of three separate experiments with similar results. The data in (b) are mean ± S.D. from a single experiment with three replicate dishes of cell per data point; similar results were obtained in two additional experiments

    Cell Mol Life Sci, 2016, 73(4):883-900. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • (A) Percentage of DN3a cells in S-phase (as gated on DAPI profile) from control (Zfp36l1/2fl/fl) and Zfp36l1/2fl/fl; CD2Cre (DCKO) mice, after 1 d of treatment with vector or palbociclib (drug).

    J Immunol, 2016, 197(7):2673-85. Palbociclib (PD-0332991) HCl purchased from Selleck.

     

    Patient tumor cell sensitivity to combinatorial treatment with histone deacetylase (HDAC)/cyclin-dependent kinase (CDK) inhibitors in 3-D culture. The effect of each drug or drug combination was assessed by fluorescent dye to identify live (green) and dead cells (red). Cells from breast reduction patients were used as non-cancer control in the assay.

    Pharmacogenomics J 2013 13(1), 94-104. Palbociclib (PD-0332991) HCl purchased from Selleck.

  •  

    Cdk4 is upregulated in ARMS and mMSCs transfected with PAX7-FKHR fusion gene (MP7F), and can be specifi cally inhibited. D: IF results showing overexpression of cdk4 in MP7F cells compared to parental mMSCs and reduced expression of cdk4 after treatment of MP7F cells with the cdk4 inhibitor, PD-0332991. E: IF results showing MyoD1 expression in parental mMSCs cells, and MP7F cells untreated and after treatment with the cdk4 inhibitor, PD-0332991.

    Clin Transl Oncol 2012 14(3), 197-206 . Palbociclib (PD-0332991) HCl purchased from Selleck.

    WM3734 melanoma cells were treated by PD-0332991 for 36 hours; melanoma cells treated by Doxorubicin (DXR)  at 0.5 μM is included as a control.

     

     

    Dr. Gao Zhang of University of Pennsylvania. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • Serum-deprived T98G glioma cells are restimulated with serum(FBS) with or without 1 μΜ PD-0332991.

     

     

    Dr. Sabine Paternot and Dr Pierre Roger of IRIBHM, ULB, Brussels. Palbociclib (PD-0332991) HCl purchased from Selleck.

    P16INK4A knockdown in INK4A/ARF-wt human glioma cell LN319 potentiates PDGF-Apromoted anchorage-dependent growth in vitro. Soft agar growth of Ink4a/Arf-deficient mAst and LN444 cells treated with PD0332991. (A) IB analysis. (B) Quantification of soft agar assays. β-actin was used as a loading control in all IB experiments. Data are presented as mean ± s.d. and representative of two independent experiments. **, P < 0.01; ***, P < 0.001

    Dr. Kun-Wei Liu from University of Pittsburgh. Palbociclib (PD-0332991) HCl purchased from Selleck.

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Description Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.
Features Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).
Targets
CDK4/CyclinD3 [1]
(Cell-free assay)
CDK4/CyclinD1 [1]
(Cell-free assay)
CDK6/CyclinD2 [1]
(Cell-free assay)
9 nM 11 nM 15 nM
In vitro

PD 0332991 has little effect on other protein kinases including EGFR, FGFR, PGFR, IR. PD 0332991 is a non-ATP competitive inhibitor of Cdk4. PD 0332991 inhibits MDA-MB-435 breast carcinoma cells with IC50 of 66 nM, which is due to reduced Rb phosphorylation at Ser780. PD 0332991 inhibits thymidine incorporation into the DNA of Rb-positive human breast, colon, and lung carcinomas as well as human leukemias, with IC50 values ranging from 0.04-0.17 μM. PD 0332991 shows no activity in Rb-negative cells. PD 0332991 causes an accumulation of cells in G1 in MDA-MB-453 breast and Colo-205 carcinoma cells. [1] PD 0332991 also shows activity in 5T33MM myeloma cells (immunocompetent model) and sensitizes the cells to killing by bortezomib. [2] PD 0332991 inhibits luminal ER-positive as well as HER2-amplified breast cancer cell lines including MDA-MB-175, ZR-75-30, CAMA-1, MDA-MB-134, HCC-202 and UACC-893. PD 0332991 enhances the activity of tamoxifen and trastuzumab in these cell lines. PD 0332991 enhances the sensitivity of tamoxifen in the MCF7 tamoxifen-resistant cells. [3] A recent study shows that PD 0332991 could suppress malignant rhabdoid tumor (MRT) cell lines including MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS and the sensitivity of the MRT cell lines to PD 0332991 is inversely correlated with expression of p16. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MOLM13 MWjLbY5ie2ViQYPzZZk> M2e1clI1KGh? MnzYTY5pcWKrdHnvckBw\iCFRFu0JIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gVoIheGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkCwNkDPxE1? NUW1[nN{OjR4NEGxNFM>
COLO205 NWSyPG96T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XxPVczKGh? M2\HeGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2W|c3XkJIF{KGmwY3;ydI9z[XSrb36gc4YhYzOKXYTofY1q\GmwZTDpcpRwKESQQTD3bZRpKEmFNUCgc4YhOC5yM{[g{txO NIToSlIzPDZ2MUGwNy=>
U937 M4i3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvxeml4PzJiaB?= M3e4XGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2W|c3XkJIF{KGmwY3;ydI9z[XSrb36gc4YhYzOKXYTofY1q\GmwZTDpcpRwKESQQTD3bZRpKEmFNUCgc4YhOC5zNDFOwG0> NGnUXZMzPDZ2MUGwNy=>
MOLM13 NWDTcId5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPOVHh7PzJiaB?= M3u5VmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTV;MUVE{KGOnbHzzJIhiemKxcnnu[{BHVFR|IFnUSEBufXSjboSgZZN{\XO|ZXSgZZMhcW6lb4Lwc5JifGmxbjDv[kBcO0ifdHj5cYllcW6nIHnueI8hTE6DIIfpeIghUUN3MDDv[kAxNjB7NjFOwG0> NEK3dG4zPDZ2MUGwNy=>
MOLM13 M2Lh[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HwfVczKGh? Mme3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDzc5Ji\mWwaXKtdoV{cXO2YX70JIh2dWGwIF3PUG0yOyClZXzsd{Bie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt|SG30bJlucWSrbnWgbY51dyCGTlGge4l1cCCLQ{WwJI9nKDBwMEm2JO69VQ>? M4fD[|I1PjRzMUCz
MDA-MB-435 NHvIVnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjNd|kzPCCq NUezWoJoUUN3ME2wMlE3KM7:TR?= MnjnNVU5ODF6M{G=
K562 M4rHd2N6fG:2b4jpZ{BCe3OjeR?= MX65OkBp NIjyPGpFVVOR NWmxO2RpUUN3ME2yJO69VQ>? M{HWWFI1PDF5NU[2
DU145 Mly2R5l1d3SxeHnjJGF{e2G7 MlmwPVYhcA>? NUHnZlBKTE2VTx?= NHXpUmlKSzVyPUeuOUDPxE1? MXKyOFQyPzV4Nh?=
MDA-MB-231 M4GxbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XYZ|Eh|ryP MXiyOEBp MVnEUXNQ NHHqSWpE\WyuIHP5Z4xmKGG{cnXzeEBie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhTzFicHjhd4U> MUiyOFQyPzV4Nh?=
MCF7 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1:5VVEh|ryP MmPRNlQhcA>? NIXJbHlFVVOR NFK2cmtE\WyuIHP5Z4xmKGG{cnXzeEBie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhTzFicHjhd4U> MXuyOFQyPzV4Nh?=
MCF7 MmLFT4lv[XOnIFHzd4F6 Mo[3OUDPxE1? MYCyOEBp MoDNSG1UVw>? MnzlTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDDSGs1N2O7Y3zpcmQyKGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhemW2aX7vZoxie3SxbXGgdIhwe3Cqb4L5cIF1cW:wIHH0JHNmejd6MB?= NESxRpAzPDRzN{W2Oi=>
MDA-MB-231 NHLmfotMcW6jc3WgRZN{[Xl? NGDNdYI2KM7:TR?= MUmyOEBp M2TTXGROW09? M33McWlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgR2RMPC:leXPsbY5FOSCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHKndHnuc4Jt[XO2b33hJJBpd3OyaH;yfYxifGmxbjDheEBU\XJ5OEC= NUHsTpdmOjR2MUe1OlY>
MDA-MB-231 NFHyWIVHfW6ldHnvckBCe3OjeR?= M2SwS|EuOTBizszN MnLINlQhcA>? Mn\NSG1UVw>? NXj3dZlV\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppd{Bie3Onc4Pl[EBieyCSQWLQJINt\WG4YXfl MkTQNlQ1OTd3Nk[=
MCF7 MY\GeY5kfGmxbjDBd5NigQ>? MUGxMVExKM7:TR?= NYDLZm9rOjRiaB?= Mlv6SG1UVw>? NUfhUJNj\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppd{Bie3Onc4Pl[EBieyCSQWLQJINt\WG4YXfl NG\F[3UzPDRzN{W2Oi=>
MDA-MB-231 NX3BbXUzTnWwY4Tpc44hSXO|YYm= NUPHfnp[OC53LUGg{txO NV30U2N7PDhiaB?= M1z4SWROW09? M{fQR4hieyCwbzDD[YxtKGO7Y3zlJIFzemW|dDDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25iYYSgd5VjNUdzIIDoZZNm MYSyOFQyPzV4Nh?=
MCF7 NUDyeXpPTnWwY4Tpc44hSXO|YYm= MUGwMlUuOSEQvF2= NVzyWmw1PDhiaB?= Mmm5SG1UVw>? NXHod5VScGG|IH7vJGNmdGxiY4njcIUh[XK{ZYP0JIF{e2W|c3XkJIF{KGGlY4XteYxifGmxbjDheEB{fWJvR{GgdIhie2V? NGfYWIYzPDRzN{W2Oi=>
697 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLwfJd4UUN3ME2xOFgvOzhibl2= MWnTRW5ITVJ?
P12-ICHIKAWA MlzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTl4LkC0JI5O MkHXV2FPT0WU
NB69 NEjRb3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jlW2lEPTB;MU[xMlghdk1? NX;EbGpUW0GQR1XS
EoL-1 M4LVRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLKOHpKSzVyPUG4O{4zPiCwTR?= MYHTRW5ITVJ?
BHT-101 NETqdmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2r0[GlEPTB;MUm4MlI2KG6P Mk\vV2FPT0WU
SK-NEP-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPRRVdpUUN3ME2yNlAvODJibl2= MUHTRW5ITVJ?
MHH-NB-11 MmfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX61VpF6UUN3ME2yNlAvOTlibl2= MV\TRW5ITVJ?
AsPC-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWP2NVdKUUN3ME2yOVIvPTNibl2= NH3yOnJUSU6JRWK=
ES1 M2nhVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEKyWZlKSzVyPUK1Ok4zPSCwTR?= M1mybHNCVkeHUh?=
LAMA-84 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33LTGlEPTB;MkW4MlE6KG6P M2\VNnNCVkeHUh?=
MOLT-16 M{HDfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTJ3OD60PUBvVQ>? M3zGTnNCVkeHUh?=
ES7 NWTTXlBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7QOIhKSzVyPUK3N{4xQSCwTR?= M1zZTnNCVkeHUh?=
KY821 M3HZPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rC[mlEPTB;M{G0MlEhdk1? MXrTRW5ITVJ?
RT-112 Ml;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7YTWM2OD1|MkGuNFUhdk1? NXLCblhqW0GQR1XS
HL-60 Mmi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\TSGlEPTB;M{SwMlY3KG6P NXTwcHZUW0GQR1XS
MOLT-4 NX30SIJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH[4fmtKSzVyPUO0OU4yOyCwTR?= NW\6W5l3W0GQR1XS
KARPAS-45 NV7kdmdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXMUHZKSzVyPUO3Ok4yPiCwTR?= NWT6RoQzW0GQR1XS
SK-N-AS NX3uUGhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPhWWZKUUN3ME2zPFcvQDNibl2= MlzXV2FPT0WU
CTB-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjt[JBGUUN3ME20NFUvODJibl2= Mn6zV2FPT0WU
NKM-1 MlO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4SxVWlEPTB;NEGxMlg6KG6P NXuzcXV[W0GQR1XS
HTC-C3 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nENmlEPTB;NEOyMlk2KG6P MWXTRW5ITVJ?
BE-13 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfUPVFKSzVyPUS0OE4zPyCwTR?= NGLCTGJUSU6JRWK=
KOSC-2 NU[4VWtjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7VdVFKSzVyPUS2Ok46KG6P M171dXNCVkeHUh?=
NB14 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jlV2lEPTB;NEizMlU5KG6P NXLJZ41rW0GQR1XS
CAL-27 NHrSR45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvLTWM2OD12OUSuOVkhdk1? MYTTRW5ITVJ?
H9 NWjrO4djT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTR7NT60N{BvVQ>? MnP2V2FPT0WU
RS4-11 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjSTWM2OD13MESuO|Mhdk1? M3H5SnNCVkeHUh?=
PA-1 NGDzSGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTVyOT64OkBvVQ>? M4fwS3NCVkeHUh?=
MV-4-11 M{m4cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTVzMz64OUBvVQ>? MnjhV2FPT0WU
OS-RC-2 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnP3TWM2OD13MkGuOlIhdk1? MmrpV2FPT0WU
RPMI-8226 MoDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUD3d3VDUUN3ME21NlYvQDZibl2= NEfPdHBUSU6JRWK=
HGC-27 NXzKRWM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\zbpk1UUN3ME21OlQvQTlibl2= MkPsV2FPT0WU
CHP-212 MmHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPzdJhKUUN3ME21PVMvPTlibl2= MX\TRW5ITVJ?
NB10 MljHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PyUmlEPTB;NUm5MlE5KG6P MXjTRW5ITVJ?
HH NHHUR5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\TNYpUUUN3ME21PVkvPDNibl2= NXHWV4hrW0GQR1XS
EW-16 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrG[nNKSzVyPU[wN{42OiCwTR?= MkHvV2FPT0WU
ES8 NWK1NJptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVyxUINqUUN3ME22NFUvOjFibl2= M1Swb3NCVkeHUh?=
HAL-01 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjaTWM2OD14MEWuOlchdk1? MXjTRW5ITVJ?
A204 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\KTWM2OD14M{OuPVEhdk1? NU\R[lZXW0GQR1XS
MHH-PREB-1 NWn4R4lxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTafZBlUUN3ME22N|YvQTlibl2= Mnf0V2FPT0WU
EM-2 NH;x[HZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vXbGlEPTB;NkWwMlY1KG6P M1\vVnNCVkeHUh?=
BV-173 MlvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;wTWM2OD14NUKuOFghdk1? MlX5V2FPT0WU
ONS-76 NVG5dIJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTZ5Nz64NkBvVQ>? NVP0bVliW0GQR1XS
KM-H2 NVSxeXllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXe1PFhjUUN3ME22PVUvPTRibl2= NVOxcpZUW0GQR1XS
D-263MG M1Sxemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTdzNz6xNkBvVQ>? MX7TRW5ITVJ?
ES3 MlnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnNRnJFUUN3ME23NlgvQTNibl2= MVvTRW5ITVJ?
VA-ES-BJ NHz3XpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjY[|JKSzVyPUezNk4zPyCwTR?= MoPWV2FPT0WU
NBsusSR MkTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTNSoNLUUN3ME23OFIvQTlibl2= Ml\hV2FPT0WU
NCI-H520 MnT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonRTWM2OD15NE[uOVIhdk1? MVvTRW5ITVJ?
ES5 NYr5cVZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHsWJZKSzVyPUe1Nk45KG6P MkPMV2FPT0WU
T-24 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jueWlEPTB;N{e4MlcyKG6P MkS5V2FPT0WU
SW962 MlzOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{GwdmlEPTB;OEC4MlY{KG6P M4nXbXNCVkeHUh?=
EW-3 NWKzT3lFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHj5WpdKSzVyPUiwPE44PiCwTR?= MVfTRW5ITVJ?
RXF393 NXvmdIFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3NTWM2OD16MUKuO|khdk1? NFTMR5NUSU6JRWK=
U251 M{[xbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIT6VY1KSzVyPUixN{45QCCwTR?= MVjTRW5ITVJ?
CAMA-1 MnfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;tTWM2OD16M{OuPVQhdk1? Ml3XV2FPT0WU
JVM-3 M{X0W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTh3MT63PEBvVQ>? M4n2eHNCVkeHUh?=
COLO-800 NVv3PWhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTh7Nz63PEBvVQ>? MoTsV2FPT0WU
OVCAR-5 NFvCRoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLuTWM2OD17MECuNUBvVQ>? M37K[3NCVkeHUh?=
LB1047-RCC NGXjbJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPMTWM2OD17MkeuOVYhdk1? MlrQV2FPT0WU
SW954 M1S3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUT0d4VwUUN3ME25NlkvPDFibl2= NUfWUIE2W0GQR1XS
J-RT3-T3-5 NFf5T3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DpUmlEPTB;OUO2MlA3KG6P NV3WPYJEW0GQR1XS
Mewo NIfTSVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TGOmlEPTB;OUO2MlYhdk1? MXnTRW5ITVJ?
NCI-H1770 NFP6PIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTjXGRCUUN3ME25OFAvPTVibl2= M3H6RXNCVkeHUh?=
HO-1-N-1 MnGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTKTWM2OD17NkKuPFEhdk1? Mnr3V2FPT0WU
HSC-3 Mm\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTl4Nj60PEBvVQ>? NG[2UWxUSU6JRWK=
TYK-nu M1rYZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljJTWM2OD17OUiuNlUhdk1? MnXRV2FPT0WU
KYSE-150 M{jodWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLQVo01UUN3ME2xMlAxODd4IN88US=> MlXEV2FPT0WU
SN12C MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjrTWM2OD1zLkCwPFc2KM7:TR?= M33tSXNCVkeHUh?=
MOLT-13 NUXPUFA4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTFwMEG0NlEh|ryP MmLVV2FPT0WU
TE-11 NFPweYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHxSWlkUUN3ME2xMlA1QDF{IN88US=> NVnGOpJFW0GQR1XS
DB NH\Ke3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTFwMEeyO|Mh|ryP Ml3XV2FPT0WU
CAL-39 MnjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rkV2lEPTB;MT6wO|UzOiEQvF2= MVvTRW5ITVJ?
A3-KAW M{fPbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrtTWM2OD1zLkC4OFA5KM7:TR?= MoDkV2FPT0WU
CHP-134 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorSTWM2OD1zLkGxPFA4KM7:TR?= MUTTRW5ITVJ?
TGW MmmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH20[lRKSzVyPUGuNVI{QTVizszN NH7TOWJUSU6JRWK=
QIMR-WIL MnHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjRTWM2OD1zLkGzNVM1KM7:TR?= NVPCSVBMW0GQR1XS
NCI-SNU-1 M4DQU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnK[FBKSzVyPUGuNVY{PTRizszN Mm\5V2FPT0WU
CGTH-W-1 M3jLWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHMZphKSzVyPUGuNVcyQDZizszN Ml7FV2FPT0WU
MHH-ES-1 NHvQeGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PUcGlEPTB;MT6xO|k5PiEQvF2= MUHTRW5ITVJ?
LB2241-RCC M3zGWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2L1TGlEPTB;MT6xPFYzKM7:TR?= M1y5cnNCVkeHUh?=
ML-2 MnzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLS[YN2UUN3ME2xMlIxPzN2IN88US=> MofDV2FPT0WU
COR-L23 M1jzU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnaOpFKSzVyPUGuNlI6OzNizszN NEjHU2lUSU6JRWK=
BFTC-905 NXrYOlRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1v2O2lEPTB;MT6yOFI3PyEQvF2= MU\TRW5ITVJ?
Hs-578-T MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTyRoxvUUN3ME2xMlI2QDF5IN88US=> NUjr[GZUW0GQR1XS
KG-1 NXXzfWhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUn3U49vUUN3ME2xMlI3Pjh4IN88US=> MorlV2FPT0WU
HEL MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\qVI9SUUN3ME2xMlI6OzN6IN88US=> MkPIV2FPT0WU
A549 MlHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3myOGlEPTB;MT6yPVM6QSEQvF2= M4OxW3NCVkeHUh?=
COLO-741 MknnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDyXIpzUUN3ME2xMlMzODh7IN88US=> M4X0PXNCVkeHUh?=
PC-3 MmDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHPTWM2OD1zLkO1NlIyKM7:TR?= M2raN3NCVkeHUh?=
HOS MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnPc|Z5UUN3ME2xMlM2Ojl4IN88US=> NYD6RlJzW0GQR1XS
HT-1080 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1G1WWlEPTB;MT6zO|UyQSEQvF2= Mkj2V2FPT0WU
TE-8 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUflRVNuUUN3ME2xMlQyPzd2IN88US=> MVnTRW5ITVJ?
BHY MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDkfIdvUUN3ME2xMlQ3QTJ|IN88US=> M{XzfHNCVkeHUh?=
BB65-RCC NGXOPZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTFwNUC1Nlgh|ryP NInZfm9USU6JRWK=
HN NGiwdGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;JPZZjUUN3ME2xMlU1ODdzIN88US=> NITQNpRUSU6JRWK=
NCI-H441 NWjDco9ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjaSlZ6UUN3ME2xMlU1QTB5IN88US=> NHXnbGFUSU6JRWK=
RPMI-8866 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\hSGJKUUN3ME2xMlU5PTB5IN88US=> MmfXV2FPT0WU
CAL-62 NW\SNWtuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk[3TWM2OD1zLk[wPFYzKM7:TR?= MVXTRW5ITVJ?
MG-63 NFfXNJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTFwNkG4NVMh|ryP Mn7CV2FPT0WU
SK-LU-1 M1jIN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXH1cFdjUUN3ME2xMlYzOTV{IN88US=> NHrxVo5USU6JRWK=
BCPAP M1rkcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXMSGR3UUN3ME2xMlY3PDV5IN88US=> MkDQV2FPT0WU
22RV1 NILRUJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTFwNke4OFMh|ryP NILTVZlUSU6JRWK=
T47D NFXDeVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnZTWM2OD1zLk[4NFYyKM7:TR?= M2\PdnNCVkeHUh?=
MSTO-211H NWjzOYJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLpTWM2OD1zLk[5OlA{KM7:TR?= NVrifFlMW0GQR1XS
DEL MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3yy[2lEPTB;MT63NFI4OyEQvF2= NWL5R2VXW0GQR1XS
H4 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTFwN{OyNVIh|ryP MnPuV2FPT0WU
CAL-51 NUnSbXZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTFwN{S4OVUh|ryP NWnPOWl1W0GQR1XS
ABC-1 NUHacWdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzpTWM2OD1zLke4OVgzKM7:TR?= M2T2THNCVkeHUh?=
MZ2-MEL NYj3foNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTFwN{m1OFIh|ryP MWPTRW5ITVJ?
YKG-1 NWfGbohmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfxTWM2OD1zLkixNFYyKM7:TR?= MULTRW5ITVJ?
KM12 MkPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTFwOEG2NFIh|ryP NY\OfWR4W0GQR1XS
L-363 NXXEXVBpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XLPWlEPTB;MT64O|QyOiEQvF2= M2jFcXNCVkeHUh?=
KU812 NFfHZ5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfFVWJKSzVyPUGuPFkzQDJizszN M2H4RXNCVkeHUh?=
LOXIMVI NICwRZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\sTWM2OD1zLkmxNlI5KM7:TR?= NYrWS|E5W0GQR1XS
G-401 MkS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTFwOUK0Nlgh|ryP M13XR3NCVkeHUh?=
SW780 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DIbGlEPTB;MT65OlI1PiEQvF2= NIK0R2xUSU6JRWK=
SW872 M{nzNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTFwOUizN{DPxE1? MlXZV2FPT0WU
NB7 MoTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTFwOUmzNlMh|ryP M2LRcnNCVkeHUh?=
T98G NUDTTpVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrNTJpKSzVyPUKuNFA3PjZizszN NVjyT2o5W0GQR1XS
SW1710 M1;SWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX63b2pKUUN3ME2yMlA3QTR3IN88US=> Mk\VV2FPT0WU
NCI-H1573 Mm\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;5cphoUUN3ME2yMlA4Ojl6IN88US=> NETZNlhUSU6JRWK=
KE-37 Moi3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jTTGlEPTB;Mj6wPFk2OSEQvF2= NX;wUItUW0GQR1XS
786-0 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHITWJ6UUN3ME2yMlE2PDN7IN88US=> NGXPPWNUSU6JRWK=
SAS NV;3O3VTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmr2TWM2OD1{LkKwN|c1KM7:TR?= NGTIc4FUSU6JRWK=
CAL-54 MlTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPSdI5jUUN3ME2yMlIxPDF|IN88US=> MVXTRW5ITVJ?
SF268 M{fkTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XB[mlEPTB;Mj6yN|EzOiEQvF2= NHn5N4hUSU6JRWK=
SW620 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TFZ2lEPTB;Mj6yOlE3QSEQvF2= MkD1V2FPT0WU
MN-60 NYLPPG5lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHj6WmNKSzVyPUKuN|ExPiEQvF2= NHm0SZZUSU6JRWK=
EFO-27 M2DYPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTJwM{KwOVgh|ryP NWXFPIRPW0GQR1XS
NCI-H747 NUHIcJh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTJwM{KxPVkh|ryP MXHTRW5ITVJ?
HCC2218 NInVUXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHHTWM2OD1{LkO1N|c1KM7:TR?= NUHsSoFIW0GQR1XS
MIA-PaCa-2 NVLVSmp{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTJwM{[0N|ch|ryP M1PUenNCVkeHUh?=
SJSA-1 Ml\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\OTG1KUUN3ME2yMlM4Pzl4IN88US=> MkXNV2FPT0WU
RKO NVHXXYVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDDN5dKSzVyPUKuN|g1QTZizszN MkDFV2FPT0WU
NB6 MoraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1H4VmlEPTB;Mj60NFM4PCEQvF2= NHjLR|JUSU6JRWK=
ES4 MkntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jLUmlEPTB;Mj60OVQzOiEQvF2= Mk[0V2FPT0WU
EGI-1 Mom3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTqTWM2OD1{LkS2PFg{KM7:TR?= M2TOOXNCVkeHUh?=
CTV-1 NHuyTXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHGTWM2OD1{LkWyO|c{KM7:TR?= M3i3SnNCVkeHUh?=
NCI-H1355 NFqyVIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnm1TWM2OD1{LkW1PVUyKM7:TR?= M3HPdnNCVkeHUh?=
GT3TKB Mln1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\OZWtKSzVyPUKuOVkyQTlizszN Ml[wV2FPT0WU
SK-HEP-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2GxWmlEPTB;Mj61PVI3PiEQvF2= M1fkT3NCVkeHUh?=
GAMG Mnu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LKOWlEPTB;Mj61PVM6PCEQvF2= NH\HVnRUSU6JRWK=
SK-MES-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3uwWWlEPTB;Mj62NVgxOyEQvF2= MnXMV2FPT0WU
RO82-W-1 MmP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvkTWM2OD1{Lk[yNFU4KM7:TR?= MlvvV2FPT0WU
ECC10 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTJwN{CyNFYh|ryP MlO4V2FPT0WU
MCF7 M3ji[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTUTWM2OD1{LkexOFY1KM7:TR?= NHznR4dUSU6JRWK=
D-283MED NGPZOZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFy3NWFKSzVyPUKuO|I1OyEQvF2= M{jRU3NCVkeHUh?=
RPMI-7951 NEnMWlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfJN24{UUN3ME2yMlc2Pjl2IN88US=> NHTrZnlUSU6JRWK=
Ramos-2G6-4C10 M3zGdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTJwN{ewPVkh|ryP M4\Qe3NCVkeHUh?=
KGN MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\YTWM2OD1{LkixPFg1KM7:TR?= MVLTRW5ITVJ?
NUGC-3 MlHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7pfFlGUUN3ME2yMlgzPTB3IN88US=> NYDJZoZtW0GQR1XS
NCI-H292 M3TXTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PP[WlEPTB;Mj64OVA2OyEQvF2= MoOyV2FPT0WU
Becker M1XZVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3r0[GlEPTB;Mj65OVg{OiEQvF2= NUPlcFB1W0GQR1XS
NCI-H1299 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojITWM2OD1|LkC1NlY{KM7:TR?= MnXhV2FPT0WU
ETK-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvqToJZUUN3ME2zMlA2PDNizszN MoTtV2FPT0WU
TK10 NVr4O4NTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU[xWYZJUUN3ME2zMlIxOTZ3IN88US=> NELhO|dUSU6JRWK=
VMRC-RCZ M4TEOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzqTWM2OD1|LkO2OFg5KM7:TR?= NFXSVZdUSU6JRWK=
YH-13 Mn60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW[2[oFVUUN3ME2zMlQ1ODd7IN88US=> NHmwbGJUSU6JRWK=
DU-145 NYHwbG5VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTNwNE[yOlkh|ryP NVzGb2U6W0GQR1XS
SW1088 NIrlUIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;KOmlEPTB;Mz60O|Q4KM7:TR?= M17NUHNCVkeHUh?=
HOP-92 NXywfFJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHJTWM2OD1|LkWwN|QzKM7:TR?= NGLxXWVUSU6JRWK=
KP-N-YS MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzrTZpKSzVyPUOuOlIyOzlizszN NX3IS5djW0GQR1XS
NCI-H460 NHq3UJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPmd|M1UUN3ME2zMlY3PzNizszN M2fJeXNCVkeHUh?=
U-2-OS Moj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLxb4tKSzVyPUOuO|I2OzVizszN NWnm[pl3W0GQR1XS
A101D NYjKW2hvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTzSlBqUUN3ME2zMlc3QTN4IN88US=> M1j2PHNCVkeHUh?=
MDA-MB-231 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;4TWM2OD1|LkixPVUyKM7:TR?= NX:5NHhtW0GQR1XS
IST-MES1 M3\DN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rsZ2lEPTB;Mz64N|Ih|ryP M1zmfXNCVkeHUh?=
COR-L105 NI\xU2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHZTWM2OD12LkCxPEDPxE1? NFjNWZFUSU6JRWK=
NCI-H1437 NFHVVoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\CWpZMUUN3ME20MlAzOzB{IN88US=> NYfmNI5HW0GQR1XS
CAL-85-1 MmPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLF[pBFUUN3ME20MlAzPDZzIN88US=> M3jOSXNCVkeHUh?=
MZ1-PC MnHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTRwMUi1OVYh|ryP NIT1ZXpUSU6JRWK=
VM-CUB-1 M{DicGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWP2[WZ2UUN3ME20MlMyOjh2IN88US=> NWjhfWdxW0GQR1XS
CHL-1 MkjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPaVIpKSzVyPUSuN|IyPjlizszN MX\TRW5ITVJ?
MDA-MB-361 NYPxUlJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LZbWlEPTB;ND6zN|E2OyEQvF2= NGTZRoxUSU6JRWK=
NCI-H661 NH\HPIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTRwNUCwPVIh|ryP MYPTRW5ITVJ?
EW-11 M3W0dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\HSmlEPTB;ND61NlI{OSEQvF2= MWDTRW5ITVJ?
BEN NYf1UlJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzGTWM2OD12LkWyPFE2KM7:TR?= NUj5OIJvW0GQR1XS
BFTC-909 M4fxTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIC1Wm5KSzVyPUSuOVYzPzVizszN Mn;pV2FPT0WU
NCI-H2087 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLYbIxyUUN3ME20MlU5OTZ2IN88US=> Mn7XV2FPT0WU
RVH-421 NIX5bZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrZeYVMUUN3ME20MlY3PjlizszN NHv6V21USU6JRWK=
P30-OHK MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPGdGxqUUN3ME20MlY5ODB6IN88US=> MXfTRW5ITVJ?
NCI-H28 MoHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fXW2lEPTB;ND64NVY3OSEQvF2= NXvTWW9MW0GQR1XS
ES6 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInwVmdKSzVyPUSuPFMxOTZizszN NVrFWlhsW0GQR1XS
769-P NX;PPGtqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF74RXpKSzVyPUSuPFU6OjZizszN Ml;xV2FPT0WU
OE33 MkLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF[4bYdKSzVyPUSuPFgyPjFizszN NGrQco9USU6JRWK=
SW982 NVfx[XlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTRwOUWwOlEh|ryP Mn\sV2FPT0WU
A388 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2[4NWlEPTB;NT6wNlk5OyEQvF2= MmjGV2FPT0WU
TI-73 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TqV2lEPTB;NT6wOlE6PCEQvF2= M{PDc3NCVkeHUh?=
HCT-116 M2e5Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLTVIpKSzVyPUWuNFk5QDlizszN NVHWSFBZW0GQR1XS
HuP-T3 M3fwOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnNTWM2OD13LkG4O|A6KM7:TR?= MWPTRW5ITVJ?
G-402 M1n1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTVwMUm0NVYh|ryP MlnuV2FPT0WU
NCI-H1792 M3fYdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;DSmlEPTB;NT6yOFYzOiEQvF2= MWHTRW5ITVJ?
NCI-H209 NWjiSGtpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYT6NJVQUUN3ME21MlI2QTR{IN88US=> NIOxeXlUSU6JRWK=
NCI-H1650 NUC4XXIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDEb|hOUUN3ME21MlMxPjN2IN88US=> MmXOV2FPT0WU
LCLC-97TM1 M1jTXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoK2TWM2OD13LkOxPFA5KM7:TR?= MmryV2FPT0WU
S-117 NXq5[GFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfZT5dKSzVyPUWuN|Y6PzZizszN MWjTRW5ITVJ?
GI-ME-N MmPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrJTWM2OD13LkO5OlgyKM7:TR?= NUGyVHFxW0GQR1XS
NCI-H2122 NFLB[Y9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTVwNEmzPVch|ryP Mn\KV2FPT0WU
NCI-H1793 NFnwcI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnyUHExUUN3ME21MlY4PTl|IN88US=> M2\hR3NCVkeHUh?=
C2BBe1 M4T2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTVwN{CwPFgh|ryP MVrTRW5ITVJ?
TE-12 NWnxVpRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rvR2lEPTB;NT64NFU2PiEQvF2= NX7QR|BQW0GQR1XS
LCLC-103H MlGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrMOpk2UUN3ME21MlkyPyEQvF2= NUfTXXJEW0GQR1XS
A673 MnK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTVwOUG5N|Ih|ryP MkLiV2FPT0WU
BB30-HNC NYTpXphET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTVwOUizOkDPxE1? NGfjOY5USU6JRWK=
SF295 M4ewNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\iS2xKSzVyPU[uNFA1OjJizszN MVLTRW5ITVJ?
KU-19-19 MlLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NED2XJpKSzVyPU[uNFE4OzFizszN NEL3dmtUSU6JRWK=
CFPAC-1 Ml3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfZR3pKSzVyPU[uNFQ1PDNizszN NWTwPG5uW0GQR1XS
LoVo NYHGR41KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;qfWlEPTB;Nj6wOVA3OyEQvF2= MWDTRW5ITVJ?
8505C NUO2bXpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXob|VNUUN3ME22MlA4PTd|IN88US=> NELYOZlUSU6JRWK=
GMS-10 MmXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnr[W0{UUN3ME22MlE2ODB{IN88US=> NWTMfVZrW0GQR1XS
Ca9-22 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITkbXdKSzVyPU[uNVY4OSEQvF2= NX7kWXZjW0GQR1XS
DOK M2HvZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHjTWM2OD14LkKyNFczKM7:TR?= M1O1SnNCVkeHUh?=
FADU NXTTb|ZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXf3cYlGUUN3ME22MlI3ODN7IN88US=> MW\TRW5ITVJ?
BxPC-3 NHXlfFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLjSGJQUUN3ME22MlI4OzJizszN MnLEV2FPT0WU
CAL-33 NIXLT2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjabGlvUUN3ME22MlI6OjBzIN88US=> MmjTV2FPT0WU
SHP-77 NHO2e2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTZwM{G1NVIh|ryP MY\TRW5ITVJ?
LXF-289 NHn4[mRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moi0TWM2OD14LkOzOFU2KM7:TR?= NV7lUlRtW0GQR1XS
GB-1 MlfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLsTWM2OD14LkO4NkDPxE1? NIO1UZFUSU6JRWK=
KS-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTFSFlKSzVyPU[uN|g1PDdizszN NWnkd3FZW0GQR1XS
D-502MG NFjEfYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDMTWM2OD14LkSyN|c3KM7:TR?= MmXIV2FPT0WU
LAN-6 NVKwUolRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXJPJB[UUN3ME22MlUyODJ|IN88US=> MYfTRW5ITVJ?
H-EMC-SS MmOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrkTWM2OD14LkW2NVQ4KM7:TR?= MWPTRW5ITVJ?
LC-2-ad MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLETWM2OD14Lk[wNFc3KM7:TR?= MoDyV2FPT0WU
NCI-H1693 NFy2SodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnK4TWM2OD14Lk[yNlE2KM7:TR?= NWHGfoZoW0GQR1XS
SK-N-FI MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XVTmlEPTB;Nj63OVA1PCEQvF2= NGfMUIVUSU6JRWK=
D-423MG MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PHTWlEPTB;Nj63OlEyPyEQvF2= NGDReGVUSU6JRWK=
KNS-42 M1G5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37yVGlEPTB;Nj63PFE6PyEQvF2= NGHTSlJUSU6JRWK=
GCT MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\TeHlVUUN3ME22Mlk{QCEQvF2= NH22TW5USU6JRWK=
DSH1 M{jE[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHqTWM2OD15LkC2N|Mh|ryP M2f0NnNCVkeHUh?=
D-247MG MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXQTWM2OD15LkC3PFgyKM7:TR?= NWrKVGNzW0GQR1XS
NCI-SNU-5 NHPzV49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;5[WlEPTB;Nz6xPFM4OSEQvF2= MXnTRW5ITVJ?
TE-6 Ml\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHxTWM2OD15LkKwOlAyKM7:TR?= M2rvbHNCVkeHUh?=
NOMO-1 NW\qZ2h2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTdwMkKxNlch|ryP NXXyTmVCW0GQR1XS
NB17 NEHFRXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvQTWM2OD15LkOwN|A6KM7:TR?= M2TJXnNCVkeHUh?=
EW-22 M{HFOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\qPYpKSzVyPUeuN|Q{PDhizszN MUXTRW5ITVJ?
EW-13 NH3OUXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTdwM{WxOlIh|ryP NWPMc5ltW0GQR1XS
DOHH-2 M{LvOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fIcmlEPTB;Nz60OFAzKM7:TR?= NWnVPI1SW0GQR1XS
TGBC1TKB NGfnO2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrzbm1vUUN3ME23MlQ6QDl7IN88US=> MlvWV2FPT0WU
GR-ST NU\Te|ByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXHbpV3UUN3ME23MlUzPTl2IN88US=> NHnadm5USU6JRWK=
KYSE-520 NYjPTG1{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTdwNUW1NVUh|ryP NYnZVpRkW0GQR1XS
CAPAN-1 NHm2O4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfueIN{UUN3ME23MlU6PTFizszN MXvTRW5ITVJ?
HCE-4 M4\qdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3yTVJuUUN3ME23MlYzOjd7IN88US=> NYHwfYJ1W0GQR1XS
MLMA MkD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTdwNkK5OVch|ryP MV7TRW5ITVJ?
HT-144 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTdwNkWzOlgh|ryP MkH6V2FPT0WU
KYSE-180 M2XyO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofMTWM2OD15LkexNVY6KM7:TR?= MkTvV2FPT0WU
TE-5 MlrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTdwOUW5O|Eh|ryP MnfpV2FPT0WU
IGROV-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlX1TWM2OD15Lkm4OVUyKM7:TR?= NFzMXYxUSU6JRWK=
NCI-H1581 M3HLc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrsTWM2OD16LkCxNkDPxE1? NYfJPHhUW0GQR1XS
SW1990 M3;JV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfSSnNmUUN3ME24MlA1PjV7IN88US=> NUTMfVh6W0GQR1XS
EFM-19 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRThwMEi1OFUh|ryP NYnINlg4W0GQR1XS
OGR-1 MlPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXG4OI9SUUN3ME24MlQ{ODJ|IN88US=> NWL4UZc2W0GQR1XS
U-118-MG NX7NUpMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{K4ZWlEPTB;OD60N|Q3OyEQvF2= M{LIfnNCVkeHUh?=
SK-OV-3 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\kXWlEPTB;OD60Olc3PSEQvF2= M3jLNHNCVkeHUh?=
KNS-62 NYDZTXVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nUe2lEPTB;OD61NVc3OSEQvF2= NFi3bWVUSU6JRWK=
GOTO NHGydpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRThwNUe2N|Uh|ryP MlrlV2FPT0WU
8305C NFK5TXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHDO2xKSzVyPUiuO|A1QDRizszN MnvuV2FPT0WU
RPMI-2650 NV65dY1XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRThwN{G5OVUh|ryP MYTTRW5ITVJ?
NEC8 NXrLfXVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjiTWM2OD16Lke0N|A4KM7:TR?= NELxPJhUSU6JRWK=
KYSE-450 M1zaTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWX4TXZqUUN3ME24Mlg3PTR6IN88US=> MXjTRW5ITVJ?
RMG-I M3zhTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTOTWM2OD17LkG0NFU5KM7:TR?= NFrhPHlUSU6JRWK=
CAKI-1 M1nTcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DR[WlEPTB;OT6zNVk4QSEQvF2= NEXTcYVUSU6JRWK=
KYSE-510 NWrl[ohZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGn2eXlKSzVyPUmuN|U4PzhizszN NXzYdZFEW0GQR1XS
A4-Fuk MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jY[GlEPTB;OT6zOlcxOSEQvF2= M175WXNCVkeHUh?=
AN3-CA M{nDUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPkOJh3UUN3ME25MlQ2PDR2IN88US=> M1;WcnNCVkeHUh?=
SK-N-DZ NY[5WJFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jzfWlEPTB;OT63Nlg1QSEQvF2= MnXuV2FPT0WU
HSC-2 NIHo[lFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{T4emlEPTB;OT63OlYzQSEQvF2= M2TKfHNCVkeHUh?=
EW-1 M2H3fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm[2TWM2OD17Lke5N|Y6KM7:TR?= M{XMV3NCVkeHUh?=
D-566MG NGW3[llIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITBb2NKSzVyPUmuPFM3PjRizszN MWPTRW5ITVJ?
COLO-792 NYTrZ|Y6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPITWM2OD17Lkm4O|Q3KM7:TR?= Mk\hV2FPT0WU
TE-10 M{noeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzWcGVKSzVyPUGwMlA{QTZizszN MULTRW5ITVJ?
NCI-H650 NUe5O3p2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nvRWlEPTB;MUCuOFI5PiEQvF2= NGTq[I5USU6JRWK=
U-266 NFfJXFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInmVJZKSzVyPUGwMlQ2PSEQvF2= NGX1PHhUSU6JRWK=
Detroit562 NWPwZYJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPUcFZKSzVyPUGxMlA2OTVizszN MnL6V2FPT0WU
NH-12 NXe1dHVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTFzLkG0OFYh|ryP NX;zepRHW0GQR1XS
CO-314 MmrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTFzLkK4OFIh|ryP NV3XbGZtW0GQR1XS
IST-MEL1 MnnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTFzLkWzNlMh|ryP M3vEdnNCVkeHUh?=
KNS-81-FD M2W0Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHncI55UUN3ME2xNU42PTJ5IN88US=> MWDTRW5ITVJ?
SW1463 M161cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnG3TWM2OD1zMT61PVg6KM7:TR?= NXPZOFBvW0GQR1XS
NCI-H23 NUPTWZQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTFzLk[1OVIh|ryP NIjEPHVUSU6JRWK=
SK-MEL-2 M3rzRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33BPGlEPTB;MUGuO|E6PyEQvF2= MYnTRW5ITVJ?
NB13 MnGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPmTm1KSzVyPUGyMlE1QTVizszN NHXaWZhUSU6JRWK=
Daoy NHTFNWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojzTWM2OD1zMj6yPFU3KM7:TR?= M3TGR3NCVkeHUh?=
NCI-H1623 NIHBeFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTubo5rUUN3ME2xNk4{QDBzIN88US=> MVPTRW5ITVJ?
NMC-G1 Mn[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnOTpczUUN3ME2xNk44OTdizszN NE\XUFVUSU6JRWK=
DK-MG M2PERmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml[xTWM2OD1zMj65OFgzKM7:TR?= MWrTRW5ITVJ?
TCCSUP NGDLPXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;3e3FZUUN3ME2xN{4yOjh2IN88US=> M3L1fHNCVkeHUh?=
SCC-15 M1LuUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTF|LkK2OVEh|ryP NWWwcGdwW0GQR1XS
NOS-1 M3ezUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXaNld7UUN3ME2xN{4zQDl|IN88US=> NUXBRVBIW0GQR1XS
RH-1 MlHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn2wTWM2OD1zMz6zNFM4KM7:TR?= MlfxV2FPT0WU
SK-MEL-3 NV7LUldCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnv[GxLUUN3ME2xN{4{PzJ6IN88US=> NHvaOoZUSU6JRWK=
NB5 M1jFcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofnTWM2OD1zMz60NFY4KM7:TR?= M2Wzd3NCVkeHUh?=
SNU-387 NHGw[|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHf5TWtKSzVyPUGzMlUxPzJizszN Mn3NV2FPT0WU
CAL-120 NUDaRXhMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;pcndKSzVyPUGzMlY4OThizszN NY\iZY1ZW0GQR1XS
Mo-T NESzXHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfTdGJkUUN3ME2xN{44ODdizszN MmGzV2FPT0WU
LNCaP-Clone-FGC NUDRZZFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\PNoFKSzVyPUGzMlc6QTJizszN M1myPXNCVkeHUh?=
CAN MknzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTF2LkCyPFgh|ryP M3O4ZXNCVkeHUh?=
SK-MEL-30 M3;sV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTF2LkC2N{DPxE1? MVvTRW5ITVJ?
COLO-678 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHieXlDUUN3ME2xOE4xQDJ{IN88US=> MkDnV2FPT0WU
SCC-9 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXK1bmY5UUN3ME2xOE4yODJzIN88US=> NUfzSlVWW0GQR1XS
KINGS-1 NFnWdIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHmc4dlUUN3ME2xOE4yPDB{IN88US=> MnfZV2FPT0WU
SL-513 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnT3TWM2OD1zND6xPFch|ryP M1HYd3NCVkeHUh?=
HLE Mn75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPveVhKSzVyPUG0MlM5PTJizszN M3LVRXNCVkeHUh?=
SW1573 M2nBbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTF2LkS0N|Uh|ryP NUPhTFlSW0GQR1XS
KYSE-140 M1Tqdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nZVmlEPTB;MUSuOlMzPyEQvF2= MV\TRW5ITVJ?
SK-PN-DW M1LUOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPrSZJKSzVyPUG0MlgxODFizszN NX[yeWtVW0GQR1XS
A253 NVLGe|EyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjSZ21KSzVyPUG1MlA3OjVizszN MY\TRW5ITVJ?
CAL-12T NHvsS4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mof0TWM2OD1zNT60OlYzKM7:TR?= NH;yb4lUSU6JRWK=
COLO-679 NIHXfXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXGTWM2OD1zNT63Olg{KM7:TR?= MlraV2FPT0WU
UACC-257 NUC2b2Q4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTF4LkGyNFEh|ryP NXPU[HdmW0GQR1XS
U-87-MG M4XEdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rWVGlEPTB;MU[uN|UzOyEQvF2= NYHtVppCW0GQR1XS
HCC1806 NUHnZ|hvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYryOWVjUUN3ME2xOk44ODdzIN88US=> M{\mRnNCVkeHUh?=
NCI-H2170 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVT5XmFmUUN3ME2xO{4zPDR6IN88US=> MVzTRW5ITVJ?
AGS MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULlbotjUUN3ME2xO{4{QDB6IN88US=> NVjlTJJEW0GQR1XS
MEL-HO M4DufWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXX0TlkzUUN3ME2xO{44PTB|IN88US=> MWrTRW5ITVJ?
SW48 M3nSXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;WTWM2OD1zNz63O|E3KM7:TR?= MmrxV2FPT0WU
HuP-T4 NUL3[WFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTF6LkCyNFYh|ryP M3\peHNCVkeHUh?=
NCI-H720 NVzTTWtoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrteXdWUUN3ME2xPE4yPDB{IN88US=> MYHTRW5ITVJ?
RCC10RGB M4nVZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnziTWM2OD1zOD6xOlk4KM7:TR?= MWfTRW5ITVJ?
HD-MY-Z NHTKVVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3ztTWlEPTB;MUiuNlI2PCEQvF2= MnHoV2FPT0WU
A427 NGXqbGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\RfmlEPTB;MUiuOVA6PCEQvF2= M1rQZXNCVkeHUh?=
HCC2998 Mn;MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTF6Lk[wOVEh|ryP NF6wSXFUSU6JRWK=
EPLC-272H NHnTS3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7zTWM2OD1zOT6wOFM1KM7:TR?= MULTRW5ITVJ?
C32 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkThTWM2OD1zOT6wOFUh|ryP MlLKV2FPT0WU
UMC-11 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPBOFRKSzVyPUG5MlIyOjNizszN MUfTRW5ITVJ?
CaR-1 MlvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXLUXpKSzVyPUG5MlY5ODRizszN NYfoVnk6W0GQR1XS
KYSE-410 M2i1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jHW2lEPTB;MUmuPVE{QSEQvF2= MWHTRW5ITVJ?
HuCCT1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3Delg1UUN3ME2yNE43Ojl2IN88US=> MYjTRW5ITVJ?
LB996-RCC NGDGNmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rV[GlEPTB;MkCuO|E3QCEQvF2= NIDC[VVUSU6JRWK=
KYSE-70 MlrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\WOJNKSzVyPUKwMlgxPTlizszN M1rzR3NCVkeHUh?=
CAL-72 M1LUdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHuWmpKSzVyPUKwMlkyPSEQvF2= NF3xcJNUSU6JRWK=
Capan-2 NIS0V5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3yTWM2OD1{MT6wOFE{KM7:TR?= NVP3[oVtW0GQR1XS
PANC-08-13 NHXY[FlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HNZWlEPTB;MkGuNlUyPSEQvF2= MmraV2FPT0WU
SBC-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jtbmlEPTB;MkGuN|A5OSEQvF2= NVP5eZpUW0GQR1XS
MFM-223 M4[0W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHhTWM2OD1{MT6zN|QzKM7:TR?= NGTCVoVUSU6JRWK=
BB49-HNC NEXrfGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XUO2lEPTB;MkGuOVcyPiEQvF2= Mn6wV2FPT0WU
SH-4 MofDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{W5VWlEPTB;MkGuOlYyQCEQvF2= NGXKUlRUSU6JRWK=
HuO9 NH\sW4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rYV2lEPTB;MkGuPVgzPSEQvF2= MlSxV2FPT0WU
AM-38 M3vPVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XiZWlEPTB;MkKuNFQ5PSEQvF2= M3zoRXNCVkeHUh?=
A431 NWfY[HY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrwTWM2OD1{Mz6yNVE6KM7:TR?= MVjTRW5ITVJ?
YAPC MlTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rk[mlEPTB;MkOuNlY2OSEQvF2= MnTVV2FPT0WU
LU-139 M4HBTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnL[41kUUN3ME2yN{41QDB7IN88US=> MojYV2FPT0WU
HEC-1 MmCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTJ|LkS5N|ch|ryP MnP1V2FPT0WU
SCC-25 MkjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2G1dWlEPTB;MkSuN|AxPiEQvF2= NUPHW45OW0GQR1XS
HT-29 M4jNZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDWbG1MUUN3ME2yOE4{QDJ|IN88US=> MniwV2FPT0WU
PC-14 M1i2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnYTWZKSzVyPUK0MlY2PzFizszN NFvsOIVUSU6JRWK=
Calu-6 NFrINoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HrTmlEPTB;MkWuOVA4OSEQvF2= MUfTRW5ITVJ?
SJRH30 NUntW2dNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTJ3Lk[0PVYh|ryP MoX2V2FPT0WU
ChaGo-K-1 NInJ[JZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3W3OGlEPTB;Mk[uNVYzQSEQvF2= NGLwWVZUSU6JRWK=
IA-LM MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7HWG5NUUN3ME2yOk4{PjR3IN88US=> NUTEVG1KW0GQR1XS
GP5d M3GzcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPyXo01UUN3ME2yOk41PDlzIN88US=> NVOxb2tlW0GQR1XS
NCI-H2291 M4jldWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2qzRWlEPTB;Mk[uOlU1OSEQvF2= MlKwV2FPT0WU
BALL-1 M3zKUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3:ydGlEPTB;Mk[uPVM6PyEQvF2= MlznV2FPT0WU
HCC1954 NGDCfXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTJ4Lkm4NFgh|ryP MUTTRW5ITVJ?
NCI-H2452 NI\tPJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTETWM2OD1{Nz60NVY{KM7:TR?= NGrBTYFUSU6JRWK=
LU-99A Mm\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jsUmlEPTB;MkeuOVU5OiEQvF2= MXjTRW5ITVJ?
NTERA-S-cl-D1 NIPSRo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjnNlRKSzVyPUK3MlczQTlizszN M3HuVHNCVkeHUh?=
PANC-10-05 Ml;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTJ5Lke3O|Uh|ryP MV\TRW5ITVJ?
NCI-H2405 M1zIOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVL0N494UUN3ME2yO{46Ozh5IN88US=> MVjTRW5ITVJ?
MDA-MB-415 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXlUVlKSzVyPUK4MlQyOzdizszN MnjvV2FPT0WU
NCI-H2342 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrnNWRKSzVyPUK4MlUzQDFizszN NF7MNJFUSU6JRWK=
TGBC24TKB NYLQV|NzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFW4OY5KSzVyPUK4MlcyOTdizszN NFzqTJVUSU6JRWK=
LU-134-A M3yybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HZSGlEPTB;MkiuPVI3OSEQvF2= MkPiV2FPT0WU
SCC-4 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjKT5RoUUN3ME2zNU4xPDl2IN88US=> MV3TRW5ITVJ?
Saos-2 MnfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTNzLkmzNFYh|ryP NYX5NGtrW0GQR1XS
RERF-LC-MS M4TZdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTN{LkiyN|Eh|ryP MXvTRW5ITVJ?
M14 M2nVeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzSTWM2OD1|Mj65O|Y1KM7:TR?= M4PrXnNCVkeHUh?=
HPAF-II NHXiUlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzBTWM2OD1|Mz61NFEyKM7:TR?= NUHxfW06W0GQR1XS
NCI-H1755 NYD2cYZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTN2LkOzNFUh|ryP M1HGRXNCVkeHUh?=
D-392MG Mny3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1v6bGlEPTB;M{WuPFY4PCEQvF2= MXPTRW5ITVJ?
A704 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fDcWlEPTB;M{[uNFQzPyEQvF2= MmDFV2FPT0WU
CP50-MEL-B NXS4PWxiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTN4LkG5NVEh|ryP NYH6TmVuW0GQR1XS
EW-18 M3PUbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvaVIhKSzVyPUO2MlQ2OiEQvF2= NYTMdVZ2W0GQR1XS
WM-115 MlfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nYR2lEPTB;M{[uPFA6QSEQvF2= M4rp[HNCVkeHUh?=
LU-65 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTN5LkG0NVch|ryP NID3cnFUSU6JRWK=
NCI-H1563 Mn61S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LGeWlEPTB;M{euNlQ5PCEQvF2= NFXDdIZUSU6JRWK=
DBTRG-05MG M3[yTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTN6LkC2PVEh|ryP M1vxUnNCVkeHUh?=
NCI-H630 M2KzdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHq5dWpKSzVyPUO4MlQ4OTRizszN MVnTRW5ITVJ?
NCI-H1155 Ml\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETuNJZKSzVyPUO5MlI1OiEQvF2= M4X3VnNCVkeHUh?=
OVACR-3 NXPxXI1vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTN7LkmxPVUh|ryP NYPqUpE4W0GQR1XS
OAW-42 NHvPTJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmC1TWM2OD12MD60NlU5KM7:TR?= M4rnZnNCVkeHUh?=
JVM-2 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYT2cGd{UUN3ME20NU4zPDF3IN88US=> M1fhVHNCVkeHUh?=
C3A MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWL4UGZlUUN3ME20NU4{PDR5IN88US=> MUDTRW5ITVJ?
HT55 NUHIUGZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7L[Vc{UUN3ME20Nk4zQDRzIN88US=> M3PDUHNCVkeHUh?=
OVCAR-4 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUK2PG1sUUN3ME20Nk4zQTd2IN88US=> MlLFV2FPT0WU
MEG-01 M1T3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTR{LkS2NVYh|ryP NHq2OWZUSU6JRWK=
NCI-H82 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTR|Lkm4PVIh|ryP MWjTRW5ITVJ?
JEG-3 MlPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDFN4tHUUN3ME20OE46PDdizszN NH21VZVUSU6JRWK=
BPH-1 NUPVWFJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfnO4toUUN3ME20Ok4{QTl6IN88US=> MmHOV2FPT0WU
MPP-89 M1;JPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEn6XmtKSzVyPUS3MlI5QThizszN MW\TRW5ITVJ?
ALL-PO NUTydmlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHvcIVKSzVyPUS3MlQyQDhizszN M1HGZ3NCVkeHUh?=
HT M1HTXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTR5LkS5NkDPxE1? M1qwZnNCVkeHUh?=
NCI-H2347 M1W3fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjaTWM2OD12OD6wO|E2KM7:TR?= NGXPZpRUSU6JRWK=
A2780 NXfkWVhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTR7LkSyNlgh|ryP MWHTRW5ITVJ?
KARPAS-299 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjmNVNIUUN3ME20PU42OTF7IN88US=> MkPWV2FPT0WU
NCI-H1651 NYnCfnBoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPwTWM2OD12OT64PFIyKM7:TR?= NYm4ZZJnW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo PD 0332991 indicates complete tumor stasis in a MDA-MB-435 xenograft at 150 mg/kg. PD 0332991 also shows broad-spectrum antitumor activity in multiple human tumor xenografts by eliminating phospho-Rb and the proliferative marker Ki-67 from tumor tissue and down-regulation of genes under the transcriptional control of E2F. [1]

Protocol

Kinase Assay:

[1]

+ Expand

Cdk Assays:

A stock solution of PD0332991 is prepared in DMSO. CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792–928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl2, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-32P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and PD 0332991 (0.001-0.1μM). All components except the [γ-32P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-32P]ATP and the plate is incubated at 25 °C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4  °C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.
Cell Research:

[1]

+ Expand
  • Cell lines: Tumor cell lines including MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM and K562
  • Concentrations: 0.01-1 μM
  • Incubation Time: 24 hours
  • Method:

    Cells are seeded at 2 × 104 per well in a 96-well plate and incubated overnight. PD 0332991 (0.01-1 μM) is added to the wells and incubated at 37 °C for another 24 hours. [14C]Thymidine (0.1 μCi) is added to each well and incorporation of the radiolabel is allowed to proceed for 72 hours. Incorporated radioactivity is determined with a β plate counter.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Advanced stage human tumor xenografts including Colo-205, MDA-MB-435 breast, SF-295 glioblastoma, ZR-75-1 breast, PC-3 prostate, H125 lung, SW-620 colon, H23 lung and MDA-MB-468 breast (Rb negative) are established in severe combined immunodeficient mice.
  • Formulation: Dissolved in sodium lactate buffer (50 mM, pH 4.0)
  • Dosages: 0-150 mg/kg
  • Administration: Given by gavage
    (Only for Reference)

Solubility (25°C)

In vitro Water 30 mg/mL (61.98 mM)
DMSO 3 mg/mL warmed (6.19 mM)
Ethanol Insoluble
In vivo Add solvents individually and in order:
Saline
20 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 483.99
Formula

C24H29N7O2.HCl

CAS No. 827022-32-2
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03007979 Not yet recruiting Breast Cancer|Breast Carcinoma|Cancer of Breast|Malignant Tumor of Breast Washington University School of Medicine February 28, 2017 Phase 2
NCT02907918 Not yet recruiting Breast Cancer|Cancer of Breast|Breast Carcinoma Washington University School of Medicine|Pfizer February 28, 2017 Phase 2
NCT01209598 Completed Sarcoma|Liposarcoma Memorial Sloan Kettering Cancer Center|Pfizer September 23, 2010 Phase 2
NCT03054363 Not yet recruiting Breast Cancer University of Colorado, Denver March 2017 Phase 1|Phase 2
NCT03024489 Not yet recruiting Head and Neck Cancer|Locally Advanced|Unresectable Mahidol University February 2017 Phase 1|Phase 2
NCT02947685 Not yet recruiting HER-2 Positive Breast Cancer|Estrogen Receptor Positive Breast Cancer Alliance Foundation Trials, LLC.|Pfizer|German Breast Group (GBG)|Fondazione Michelangelo|PrECOG, LLC.|The Australia and New Zealand Breast Cancer Trials Group (ANZBCTG)|Alliance Foundation Trials Biorepository - Washington State University|Alliance Foundation Trials Central Imaging Core Lab - Ohio State University|Mastering Breast Cancer Initiative, LLC|Mayo Clinic Statistics and Data Center|INC Research|SOLTI Breast Cancer Research Group February 2017 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    There are two kind of Palbociclibs available: the isethionate salt or the HCl salt. I would like to know which is the main difference between them and what are they more suitable for in terms of experiment type (cell culture or in vivo animals experiments).

  • Answer:

    This two compounds are different Palbociclib salt. S1579 is the Isethionate salt, and the S1116 is the HCl salt. you can use S1116 for oral administration while S1579 is more suitable for I.P. administration.

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

Related CDK Products

Tags: buy Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl supplier | purchase Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl cost | Palbociclib (PD-0332991) HCl manufacturer | order Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID